

Systemic Therapy Education Bulletin

BC Cancer news and updates from across the province for Systemic Therapy teams

Provincial Systemic Therapy Drug Programs Under Consideration



The goal of the Education Bulletin is to support health care staff as they prepare for new treatments and to ensure safe patient care during the administration, distribution and management of new and complex treatments. These new drug treatments may also be delivered to patients prior to formal listing through manufacturer patient support programs or clinical trials. Full details around the funded indications and eligibility criteria will be available in the Protocol Summaries and summarized in the Systemic Therapy Update newsletter once funding decisions have been finalized. More details about the drugs, approved indications, and side effects can be found in the BC Cancer drug monographs, accessible from the Cancer Drug Manual [Drug Index](#).

UGOOVFOLAM

| Treatment Programs | Indication: Under Review (Refer to protocol for more details) | Associated Adverse Events |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Olaparib | Maintenance Treatment of Newly Diagnosed BRCA-Mutated Platinum Responsive Epithelial Ovarian Cancer | Possible adverse events (of any grade): <ul style="list-style-type: none"> • Anemia • Neutropenia • Thrombocytopenia • Nausea and vomiting • Skin reaction <ul style="list-style-type: none"> ○ Rash ○ Dryness ○ Itchiness • Diarrhea • Headache • Muscle/joint pain • Peripheral edema • Taste alteration • Loss of appetite • Fatigue • Myelodysplastic syndrome/acute myeloid leukemia • Pneumonitis |
| Dosing and Administration Information | | |
| <p>Pre-medications:</p> <ul style="list-style-type: none"> • Antiemetic: low to moderate emetogenicity (see SCNAUSEA) <p>Dosing and Schedule: One cycle = 28 days</p> <ul style="list-style-type: none"> • Oral olaparib 300 mg twice daily until disease progression or unacceptable toxicity for a maximum of 2 years. <p>Additional Protocol Information:</p> <ul style="list-style-type: none"> • Patients to avoid grapefruit and grapefruit juice for the duration of treatment • Concurrent use of moderate and strong CYP 3A4 inhibitors should be avoided • Dose modification options: <ul style="list-style-type: none"> ○ Oral olaparib 250 mg twice daily ○ Oral olaparib 200 mg twice daily ○ Oral olaparib 150 mg twice daily | | |

Education Bulletin Evaluation

We like to hear from you!

The goal of the Education Bulletin is to support health care staff as they prepare for new treatments and to ensure safe patient care during the administration, distribution and management of new and complex treatments. We would like to review if we are meeting this goal, and to further refine and improve how we communicate this information.

Please complete the [Education Bulletin Survey](#) by Friday, November 6th.

Your feedback is appreciated and valued.

Website Resources and Contact Information

| CONTACT INFORMATION | EMAIL |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| To subscribe or update contact information, please contact: | |
| Provincial Systemic Therapy Program | ProvincialSystemicOffice@bccancer.bc.ca |
| Systemic Therapy Education Bulletin: http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/education-bulletin | |